Open AccessResveratrol, a polyphenol phytoalexin, protects against doxorubicin‐induced cardiotoxicity
Author(s) -
Gu Jun,
Hu Wei,
Zhang Dadong
Publication year - 2015
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.12633
Subject(s) - phytoalexin , cardiotoxicity , resveratrol , polyphenol , doxorubicin , chemistry , pharmacology , medicine , biochemistry , toxicity , antioxidant , chemotherapy , organic chemistry
Doxorubicin is the mainstay of treatment for various haematological malignancies and solid tumours. However, its clinical application may be hampered by dose‐dependent cardiotoxicity. The mechanism of doxorubicin‐induced cardiotoxicity may involve various signalling pathways including free radical generation, peroxynitrite formation, calcium overloading, mitochondrial dysfunction and alteration in apoptosis and autophagy. Interestingly, the use of resveratrol in combination with doxorubicin has been reported to prevent cardiac toxicity as well as to exert a synergistic effect against tumour cells both in vivo and in vitro . Thus, the aim of this review is to summarize current knowledge and to elucidate the protective effect of resveratrol in doxorubicin‐induced cardiotoxicity.